Share on

Global Diabetic Retinopathy Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Treatment Type, Indication, End User and Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 875
Pages: 178
Formats: report pdf report excel report power bi report ppt

Diabetic Retinopathy Market Size (2022 to 2027)

As per our report, the global diabetic retinopathy market size was valued at USD 7.45 billion in 2022 and estimated to reach USD 10.4 billion by 2027, showcasing a CAGR of 6.9% from 2022 to 2027. High target disease dominance, product launches by the leading diabetic retinopathy market players, increasing strategic developments such as partnerships and agreements, and favorable research funding scenarios are the key market growth drivers.

It is a medical complication that affects the retina in the eye in diabetic patients. It impacts the blood vessels in the eye, which may lead to vision loss and blindness. Patients have to undergo an eye examination test like Visual acuity test, Pupil dilation, Ophthalmoscopy or fundus photography, Fundus Fluorescein angiography (FFA), Retinal vessel analysis, or Optical coherence tomography (OCT) to confirm the disease. As per the National Center for Biotechnology Information, the populace affected with Diabetic Retinopathy (DR) was 126 million in 2010. This value to reach 191 million by the end of 2030, which is to influence the growth of the diabetic retinopathy market at an equal pace.


Rising incidences of diabetes, inability to cope with the retinal screening of patients with diabetes and growth in the awareness among people over the diagnosis and treatment services in the hospitals are primarily expanding the global diabetic retinopathy market. Diabetic Retinopathy affects over 33% of diabetes patients and is the principal cause of blindness in the 20-79 aged population with diabetes. India, China, and Bangladesh alone are representing over 40% of the global diabetic retinopathy burden. In Africa, two-thirds of people with diabetes remain undiagnosed. About 30% of people with Diabetic Retinopathy present the greatest unmet need. In the United States, Diabetic Retinopathy is the leading cause of new cases of legal blindness among adults aged 20 to 79 years.

Additionally, increasing demand for continuous monitoring of the diseases, rising capital income in developed and developing countries, and growing elderly people populations further fuel market growth. Rising demand for cost-effective and protective treatment procedures and having the least quality diagnosis are estimated to favor the global diabetic retinopathy market growth.


Less knowledge about the treatment options, shortage of skilled ophthalmologists, and strict government rules are major restraints to the market growth.

Diabetic Retinopathy is a common diabetic eye disease; leads to eye blindness for diabetic patients. The lack of trained professionals or technically skilled professionals is the major restraints of the diabetic retinopathy market. Further, the major drawback of the diabetic retinopathy market was the costliest treatment. The availability of advanced technology and various treatment methods like laser treatment is hindering the market. Moreover, prescribing the medication for decreasing the impact of diabetic retinopathy will be a significant drawback for the market. The lengthy approval times for drugs and lack of awareness about diabetic retinopathy treatment in emerging countries like India, South Africa, etc., will affect the market growth.

Impact of COVID-19 on the global diabetic retinopathy market:

The World Health Organisation had declared the coronavirus as a pandemic. More than 200 countries declared a lockdown to stop the spread of novel coronavirus. Moreover, 110 million were affected with COVID 19, 61.9 million people were recovered, and more than 2.43 million people died. 

The pandemic has affected so many industries or markets differently. The healthcare sector has both positive and negative impacts due to novel coronavirus diseases.  Due to lockdown, all manufacturing industries, companies, and others were shut, where the supply chain got disturbed. The patients are unable to get their medicines due to a lack of supply. Moreover, due to lack of workers and strict lockdown restrictions, there is a decline in productivity; thus, there is no supply for the demand. However, the market's key players try their best to overcome the pandemic by releasing new technologies into the market.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Analysed

By Treatment Type, Indication, End User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa


This research report on the global diabetic retinopathy market has been segmented and sub-segmented based on the treatment type, indication, end-user, and region.

Diabetic Retinopathy Market - By Treatment Type:

  • Anti-Vascular Endothelial Growth Factor (VEGF) drug
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy     

Based on the treatment type, the Anti-Vascular Endothelial Growth Factor (VEGF) segment leads with the highest shares of the market, followed by the laser treatment segment. The laser treatment is further divided into focal laser treatment and scatter laser treatment. Focal laser treatment is growing tremendously with the rise in the prevalence of early diagnosis. The availability of skilled physicians in managing health disorders is significantly influencing the growth of the market. Also, increasing support from the government through investments is leveraging the growth of the market.

Diabetic Retinopathy Market - By Indication:

  • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Mild
    • Moderate
    • Severe
  • Proliferative Diabetic Retinopathy (PDR) 

Based on indication, the Non-proliferative diabetic retinopathy segment is holding dominant shares of the market. On-going research in the development of innovative procedures for diagnosing various diseases is elevating the market's growth. Increasing the scale of specialty care centers is impacting positively on the growth of the market.

Diabetic Retinopathy Market - By End-User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

Based on end-user, the Hospitals and clinics end-user segments are having the highest shares of the market. A rise in the construction activities of hospitals with the latest equipment is primarily boosting up the growth rate of the market. If the diabetes is untreated properly, it may damage blood vessels in the retina of an eye, which is leveling up the market demand. Increasing expenditure on healthcare is magnifying the growth of the diabetic retinopathy market.

Diabetic Retinopathy Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, North American remains the central revenue-generating region; this is happening due to the high obesity rates in this region. 

Europe has a large population of baby boomers. This factor helps Europe stand 2nd position in leading the highest shares in the diabetic retinopathy market.

The Asia-Pacific region to grow at the highest CAGR. The growing population of diabetes and the local people's changing lifestyles are primary factors boosting the market in the Asia Pacific. 

The profitable growth of the Asia-Pacific diabetic retinopathy market is due to many people with diabetes in this region. Emerging economies such as Japan and China in the Asia-Pacific region will grow significantly during the forecast period due to rising disposable income, growing elderly population, increased funding for diabetes research, and innovation in diagnostics. The Chinese market increases at a healthy rate, whereas Japan is the largest market in the Asia-Pacific region due to high medical expenses and increasing disposable income. Besides, increased use of Lucent to drive APAC Diabetic Retinopathy Market growth in the area.


Some of the notable companies dominating the global diabetic retinopathy market profiled in this report are Bayer Healthcare, Pfizer, Inc., Hoffmann-La Roche Ltd, Regeneron Pharmaceutical, Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science, Inc., and Ampio Pharmaceuticals Inc.       

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample